martes, 3 de septiembre de 2024

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01643-X/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esccardio24&_hsenc=p2ANqtz-_LUP2uW62zfQ4Nt8VmJiGbVuh8Lqx2ncbjCPYdnlGsIiC5IqeMEvTSohr1U97GmiQzOF6Vs8DO0bL6FSi96lDX3nH2xg&_hsmi=322301914&utm_content=322301914&utm_source=hs_email

No hay comentarios:

Publicar un comentario